RNA interference is a natural mechanism for living cells to control whether specific genes are being used. Crowned with the ...

RNA interference is a natural mechanism for living cells to control whether specific genes are being used or not.

Building sustainable product engine for innovative RNAi therapeutics to make a significant impact for patients across multiple disease indications, with first program expected to enter clinical ...

DUBLIN and LONDON, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Aerska, a biotechnology company aiming to redefine the treatment of neurological diseases, today announced it has raised $21 million in seed ...

The era of genetic medicine has arrived. As scientists continue to unravel the mysteries of humanity’s genetic blueprint, their discoveries are driving the emergence of new types of therapies such as ...

Stuart Milstein appointed Chief Platform Officer, bringing decades of experience in oligonucleotide drug development to underpin Aerska’s platform R&D Lisa Taylor Ash joins Board of Directors, ...

− Alliance pairs Alnylam’s RNAi platform and 20+ years of proprietary data with Inceptive’s foundation models and AI expertise to catalyze progress beyond rational drug design – By integrating ...

Viking Global Investors and Sofinnova Investments join a strong syndicate of existing investors including ARCH Venture Partners, Fidelity Management & Research Company and Invus Proceeds to accelerate ...

Medical innovation is accelerating, yet the path from discovery to approved treatment remains slow and resource-intensive. For many patients, that delay matters. Researchers are now exploring whether ...

Clinical Trial Application (CTA) submission marks the advancement of Tangram’s GalOmic RNAi platform into clinical development LONDON, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Tangram Therapeutics (‘Tangram’ ...

June 3 (Reuters) - Alnylam Pharmaceuticals said on Wednesday it has teamed up with artificial-intelligence biotech Inceptive in a deal worth up to $2 billion to use AI to speed up discovery of ...